

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

**FINANCIAL RESULTS
FOR THE YEAR ENDED DECEMBER 31, 2021**

This announcement is issued by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Note to Rule 13.49(1) of The Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Shareholders and potential investors of the Company are reminded that the preliminary results of the Group for the year ended December 31, 2021 (as prescribed by Rule 13.49(1) of the Listing Rules) were included in Appendix III to the prospectus of the Company dated March 21, 2022, which is available for viewing on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.recbio.cn).

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, March 31, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Liu Yong as the chairman of the board of directors and an executive director, Dr. Chen Jianping and Mr. Li Bu as executive directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Dr. Yuen Ming Fai as independent non-executive directors.